For the quarter ended March 2026, Colgate-Palmolive (CL) reported revenue of $5.32 billion, up 8.4% over the same period last year. EPS came in at $0.97, compared to $0.91 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.2 billion, representing a surprise of +2.48%. The company delivered an EPS surprise of +2.16%, with the consensus EPS estimate being $0.95.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Net Sales- Oral, Personal and Home Care- North America: $888 million compared to the $902.2 million average estimate based on two analysts. The reported number represents a change of -11% year over year.
- Net Sales- Oral, Personal and Home Care- Asia Pacific: $804 million versus the two-analyst average estimate of $759.76 million. The reported number represents a year-over-year change of +16.5%.
- Net Sales- Oral, Personal and Home Care- Europe, Middle East & Africa: $1.13 billion compared to the $1.18 billion average estimate based on two analysts. The reported number represents a change of +63.2% year over year.
- Net Sales- Oral, Personal and Home Care- Latin America: $1.31 billion versus $1.22 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.9% change.
- Net Sales- Pet Nutrition: $1.19 billion compared to the $1.17 billion average estimate based on five analysts. The reported number represents a change of +6.8% year over year.
- Net Sales- Total Oral, Personal and Home Care: $4.13 billion versus the five-analyst average estimate of $4.04 billion. The reported number represents a year-over-year change of +8.9%.
- Operating profit- Pet Nutrition: $280 million compared to the $264.48 million average estimate based on three analysts.
- Operating profit- Total Oral, Personal and Home Care: $1.03 billion versus $972.59 million estimated by three analysts on average.
View all Key Company Metrics for Colgate-Palmolive here>>>
Shares of Colgate-Palmolive have returned +0.3% over the past month versus the Zacks S&P 500 composite's +10.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpColgate-Palmolive Company (CL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
